Letter to President Trump from US doctor behind hydroxychloroquine study - urges widespread adoption of zinc/hydroxychloroquine therapy
Doctor Zelenko released the letter a few hours ago.
Here's a summary of Dr Zelenko's (and others) studies and findings.
New York, NY July 2, 2020 – Dr. Vladimir Zelenko, a New York based primary care physician, announced today that a retrospective study analyzing his patient data is available to read online at www.TheZelenkoProtocol.com. The study, which has been submitted for peer review, found that early intervention and treatment of risk stratified COVID-19 patients in an outpatient setting resulted in five times less hospitalizations and deaths. The treatment consisted of zinc, low dose hydroxychloroquine, and azithromycin.
Prior studies of COVID-19 treatments have largely been based on severely ill patients in a hospital setting, including those in intensive care with mechanical ventilation. Conversely, this study examines outcomes resulting from the early treatment of patients after their first visit to the doctor’s office. Using simple risk stratification criteria, Zelenko identified which patients required prescriptions for the triple drug therapy, and prescribed these medications for five days.
The main results show that of 141 patients who were treated with the triple therapy, only 2.8% (4/141) were hospitalized compared to 15.4% of an untreated control group (58/377) (odds ratio 0.16, 95% CI 0.06-0.5; p<0.001). Only 0.71% (1/141) patients died in the treatment group, versus 3.5% (13/377) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.16).
To produce this retrospective analysis and study, Zelenko collaborated with Dr. Roland Derwand, a German medical doctor and life science industry expert, and Professor Martin Scholz, an independent consultant and adjunct professor for experimental medicine at Heinrich Heine University, Düsseldorf, Germany. Derwand and Scholz were the first to mention the Zelenko Protocol in a scientific paper, with their recently published hypothesis paper about the possible importance of combining zinc with low dose hydroxychloroquine as a method of treating COVID-19. Derwand and Scholz also performed the data analysis and led the writing of this study while Zelenko handled all in-person treatments.
“What differentiates this study is that patients were diagnosed very early with COVID-19 in an outpatient setting and treated early on,” said Derwand. “Unfortunately, we seem to have forgotten common medical knowledge - that we want to treat any patient with an infectious disease as soon as possible. Zelenko treated his risk stratified patients immediately with the three drugs to ensure sufficient efficacy and didn’t wait for the disease to further develop.”
“It’s unfortunate that much of the media coverage surrounding hydroxychloroquine has been negative,” Zelenko continued. “These three medications are affordable, available in pill form, and work in synergy against COVID-19. This regimen works, and it happens to be the only available pre-hospital treatment to show promise.”
“Hydroxychloroquine’s main function is to allow zinc to enter the cell, while zinc is a virus killer,” Zelenko added. “Azithromycin prevents secondary bacterial infection in the lungs, and reduces the risk of pulmonary complications. So zinc is the bullet, hydroxychloroquine is the gun, and azithromycin is the protective vest.”
“This is the first study with COVID-19 outpatients that shows how a simple-to-perform outpatient risk stratification allows for rapid treatment decisions shortly after onset of symptoms,” said Professor Scholz. “The well-tolerated 5-day triple therapy resulted in a significantly lower hospitalization rate and less fatalities with no reported cardiac side effects compared with relevant public reference data of untreated patients. The magnitude of the results can substantially elevate the relevance of early use, low dose hydroxychloroquine, especially in combination with zinc. This data can be used to inform ongoing pandemic response policies as well as future clinical trials.”
About Dr. Roland Derwand
Based in Munich, Derwand is a medical doctor and life science industry expert with almost 20 years of experience. He currently heads the medical affairs department of a U.S. biotech company in Germany. His engagement and contribution to this study has been private and independent. Before he held various positions in the pharma and biotech industry with national, European and global responsibilities. He holds an M.D. from Johannes Gutenberg University in Mainz, Germany, an MBA from the PFH Private University of Applied Sciences in Göttingen, Germany, and he did his doctorate in cardiovascular physiology.
About Prof. Dr. Martin Scholz
Scholz holds a doctorate degree (Ph.D.) from Johann Wolfgang Goethe –University, Frankfurt am Main, Germany and is an adjunct professor for experimental medicine at Heinrich Heine University Düsseldorf. He also serves as managing director of the “Starts- and -Ups Consulting” company. Prior to this, Scholz served as the chief scientific officer on the executive board of LEUKOCARE AG, a biotech company he founded in 2001. Scholz received the title “professor honoris causa” at the Faculty of Medicine Marilia (FAMEMA) in São Paulo, Brasil.
About Dr. Vladimir Zelenko
Zelenko graduated from SUNY at Buffalo School of Medicine in 2000. He is Board Certified in Family Medicine and is the medical director at Monsey Family Medical Center.
If you would like more information, please visit www.thezelenkoprotocol.com